Fig. 2: Distribution of the AIMP2-DX2/AIMP2 expression ratio and its correlation with major cancer pathways in 23 cancer types from the ICGC/TCGA.

a An IGV sashimi plot to visualize the spliced junctions of the AIMP2 gene. Sequencing reads spanning across exons 1–2 and exons 1–3 were considered as AIMP2 and AIMP2-DX2 mRNAs, respectively. b Box plot of expression ratios of AIMP2-DX2/AIMP2 from 753 cancer patients’ RNA-sequencing data on the ICGC/TCGA database plotted by cancer type. Twenty three cancer types are listed in descending order of the median AIMP2-DX2/AIMP2 expression ratio. c Differentially expressed gene set analysis using the GAGE method. Each tile in this figure denotes −log₁₀(q values) of a specific pathway in each cancer type. A positive correlation is indicated by a red, while a negative correlation is denoted by blue. Box plot features: center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, individual AIMP2-DX2/AIMP2 expression ratio. ICGC the International Cancer Genome Consortium, TCGA The Cancer Genome Atlas, IGV Integrative Genomics Viewer, GAGE generally applicable gene-set enrichment, AML acute myeloid leukemia, BLCA bladder urothelial carcinoma, KICH kidney chromophobe, DLBL diffuse large B-cell lymphoma, KIRP kidney renal papillary cell carcinoma, HCC hepatocellular carcinoma, LGG low-grade glioma, GBM glioblastoma multiforme, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, TC thyroid carcinoma, GC gastric adenocarcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, SARC sarcoma, OV ovarian serous cystadenocarcinoma, BC breast invasive carcinoma, COAD colon adenocarcinoma, READ rectum adenocarcinoma, RCC kidney renal clear cell carcinoma, PRAD prostate adenocarcinoma, HNSC head and neck squamous cell carcinoma, UCEC uterine corpus endometrial carcinoma.